Clinical Trials

  • Principal Investigator

    June Y. Hou, MD
    The purpose of this study is to compare the effects of using Sodium Cridanimod in combination with the progestin (hormone therapy) megestrol acetate. Hormonal therapy on its own is generally not aneffective treatment for endometrial cancer when there are not have enough progestin receptors on tumor cells. The addition of the study drug Sodium Cridanimod to the hormone therapy could increase the level of progestin receptors in your tumor tissue, allowing the progestin to work in shrinking the tumor size. An assessment of its safety is also a purpose of the study.
  • Principal Investigator

    June Y. Hou, MD
    The study drug (TSR-042) in this study is designed to stop cancer from growing by helping your immune system recognize and fight the cancer. The Study Drug is designed to help your immune system by attaching to a protein called PD-1 and stopping one of the signals that keeps your immune system from recognizing the cancer. This may help your immune system attack and destroy the cancer cells.
  • Principal Investigator

    Ana I. Tergas, MD
    The purpose of this study is to see how well an investigational new drug and study device combination work to treat women with pre-cancerous cells of the vulva caused by human papillomavirus (HPV) and,thereby avoid surgery. To participate in this study you must have high grade squamous intraepithelial lesion (HSIL) of the vulva caused by HPV types 16 or 18.
  • Principal Investigator

    Cynthia Gyamfi-Bannerman, MD
    When women have a cesarean delivery, there is an amount of bleeding. Occasionally (in less than 5 of every 100 births) there is severe bleeding that can place the mothers health at risk. When there is too much bleeding after a cesarean delivery, women are given medicines, blood transfusions, or possibly need another surgery. Tranexamic acid is routinely used to lessen the chance of hemorrhage. It works by making your blood clot sooner. It is not routinely used for cesarean sections. We are doing this study to see if this drug also works for women who are having a cesarean section.
  • Principal Investigator

    Ana I. Tergas, MD
    The purpose of this study, which involves research, is being done to see how well an investigational new drug and study device combination will work to treat people with pre-cancerous cells on the cervix caused by human papillomavirus (HPV). The treatment combination is testing a drug, called VGX-3100, given by injection and used with the study device, CELLECTRA 5PSP, that delivers a small electric charge through 5 needles to increase the amount of the study drug taken up by muscle.

Pages